Preclinical studies suggest that DNMT1 inhibition can upregulate PD-L1 expression, cancer-testis antigens (CTAs), and other TAAs, presenting promising targets for cancer immunotherapy [132]. This evidence concerns the gene DNMT1 and cancer.